NEWS
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial
Sight Sciences (Nasdaq: SGHT) announced the publication of a new study in Clinical Ophthalmology, demonstrating the efficacy of TearCaretreatment for dry eye disease (DED). The study, titled 'Impact of TearCare on Reading Speed in Patients with Dry Eye Disease,' revealed significant improvements in various metrics:
- 52% of participants showed clinically significant improvement in reading speed
- Statistically significant improvements in IReST and MNREAD scores
- Significant enhancements in OSDI and NEI-VFQ-25 scores, measuring symptoms and vision-related quality of life
- Significant improvements in all DED sign metrics
The prospective single-center study suggests that a single TearCaretreatment can improve vision-related quality of life and reading speeds in patients with meibomian gland disease associated DED. The findings indicate that this interventional approach should be considered to reduce the disease burden of MGD associated DED.
- 52% of participants showed clinically significant improvement in reading speed
- Statistically significant improvements in IReST and MNREAD scores
- Significant enhancements in OSDI and NEI-VFQ-25 scores, measuring symptoms and vision-related quality of life
- Significant improvements in all DED sign metrics
The prospective single-center study suggests that a single TearCaretreatment can improve vision-related quality of life and reading speeds in patients with meibomian gland disease associated DED. The findings indicate that this interventional approach should be considered to reduce the disease burden of MGD associated DED.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2634Followers
107Following
28KVisitors
Follow